Introduction
Hypoglycemia is a preventable but potentially serious complication of diabetes treatment. It occurs when blood glucose falls low enough to require immediate attention and may cause sweating, tremor, hunger, confusion, weakness, impaired judgment, seizure, loss of consciousness, injury, or death. People with type 2 diabetes are not equally vulnerable. Risk rises with certain medications, previous severe episodes, older age, kidney impairment, cognitive problems, inconsistent food intake, and other clinical or social factors. The hypoglycemia risk-stratification tool developed by Andrew Karter and colleagues was important because it translated routinely available health-record information into a practical estimate of a patient’s likelihood of hypoglycemia-related emergency-department or hospital use during the following year. The tool was designed to focus preventive attention, not to replace clinical judgment or diagnose an episode.
Why Hypoglycemia Risk Assessment Matters
Modern diabetes care seeks to reduce long-term complications while avoiding harm from treatment. Glucose-lowering therapy can prevent or delay microvascular complications, but an overly intensive or poorly matched regimen may increase hypoglycemia. The risk is particularly relevant for people using insulin or sulfonylureas because these therapies can lower glucose even when a person eats less than expected, exercises more, has impaired kidney clearance, or makes a dosing error. Some people recognize early warning symptoms and treat themselves; others have diminished awareness and may progress rapidly to severe impairment.
Hypoglycemia can affect more than laboratory values. An episode may lead to falls, motor-vehicle crashes, cardiac stress, emergency treatment, fear of taking medication, and reduced confidence in self-management. Recurrent episodes can encourage patients or clinicians to maintain glucose at unnecessarily high levels, creating a conflict between immediate safety and long-term control. Risk assessment helps resolve that conflict by identifying people who may benefit from medication review, education, monitoring technology, less stringent targets, or additional support.
The Karter Hypoglycemia Risk-Stratification Tool
Karter and colleagues developed and validated their model using large populations of adults with type 2 diabetes. The original analysis considered many candidate predictors before producing a simplified tool that clinicians and health systems could apply without complex calculation. The published model estimated the twelve-month probability of an emergency-department visit or hospital admission related to hypoglycemia. It classified patients into low, intermediate, and high-risk groups, enabling care teams to direct preventive services toward those most likely to experience serious events.
A correction is necessary to the original essay: the final model was based on six variables, not “sex variables.” Those variables were a previous hypoglycemia-related emergency or hospital encounter, insulin use, sulfonylurea use, severe or end-stage kidney disease, emergency-department or hospital use for any reason during the preceding year, and age. The model’s strength was its parsimony. Each variable could be obtained from routine records, making population-level implementation more realistic than a tool requiring extensive testing or specialist interviews.
Previous Severe Hypoglycemia
A prior hypoglycemia-related emergency visit or admission is a strong warning because it shows that the patient has already experienced a clinically significant episode. The causes may include medication intensity, impaired awareness, irregular meals, cognitive difficulty, limited health literacy, alcohol use, or inadequate support. A previous event should prompt investigation rather than simple documentation. The care team needs to understand what happened, whether the circumstances persist, and whether the patient has the resources to recognize and treat future episodes.
Insulin and Sulfonylurea Use
Insulin is essential for many patients, but its glucose-lowering effect can exceed immediate physiological needs. Risk depends on insulin type, dose, timing, meal patterns, renal function, physical activity, and the person’s ability to administer and adjust therapy. Sulfonylureas stimulate insulin secretion and can also cause prolonged hypoglycemia, particularly in older adults or people with kidney impairment. Identification of these therapies does not mean they are automatically inappropriate. It means their benefits, dosing, alternatives, and monitoring requirements should be reviewed in the context of the individual patient.
Kidney Disease
Advanced kidney disease increases risk through several mechanisms. The kidneys help clear insulin and some medications, so reduced function may prolong their effects. Kidney disease can also alter appetite, nutrition, gluconeogenesis, and overall physiological reserve. A dose that was previously safe may become excessive as renal function changes. Medication review and follow-up are therefore essential, and clinicians should use current prescribing guidance for the specific therapy and level of kidney function.
Recent Acute-Care Use
Emergency-department visits or hospitalizations for any reason can indicate clinical complexity, frailty, unstable disease, or transitions in care. Hospital discharge may involve changes in medications, diet, activity, and daily assistance. Communication failures during such transitions can increase the chance of duplicate therapy or misunderstanding. Recent acute-care use is therefore not merely a statistical marker; it points to a period when reconciliation, education, and timely follow-up may prevent harm.
Age
Age contributes to risk because older adults are more likely to have multiple conditions, kidney impairment, cognitive changes, visual or dexterity limitations, and complex medication regimens. Symptoms may be less obvious, and the consequences of an episode—such as a fall or fracture—may be more severe. Age alone should never be used to deny effective treatment. It should prompt individualized goals and consideration of function, comorbidity, life expectancy, support, and patient preference.
Risk Categories and Their Interpretation
The simplified tool classified annual risk as low, intermediate, or high. In the original model, high risk represented a predicted probability above 5 percent, intermediate risk approximately 1 to 5 percent, and low risk 1 percent or less for hypoglycemia-related emergency or hospital use. These thresholds were intended to support population management. They do not state that a low-risk patient cannot experience hypoglycemia, nor do they prove that every high-risk patient will.
A risk category should initiate a clinical conversation. The estimate depends on the population and data available when the model was developed. Medication patterns, monitoring technologies, coding practices, and patient populations change over time. Before a health system applies the tool, it should examine whether the model performs adequately in its setting, whether important groups are underrepresented, and whether the preventive services attached to the alert are beneficial and equitable.
Current Clinical Classification of Hypoglycemia
The American Diabetes Association’s 2026 Standards of Care classify hypoglycemia by glucose level and clinical severity. Level 1 is glucose below 70 mg/dL but at least 54 mg/dL. This threshold is clinically important because it provides time to treat and reconsider therapy. Level 2 is glucose below 54 mg/dL, a concentration associated with neuroglycopenic risk and a need for immediate action. Level 3 is a severe event characterized by altered mental or physical functioning that requires assistance, regardless of the measured glucose value.
These levels complement the Karter tool but answer a different question. The ADA classification describes an episode; the risk tool estimates the likelihood of future acute-care use. A patient may experience frequent level 1 episodes without hospitalization, and those episodes still matter because they may precede more serious events. Conversely, a person identified as high risk may not have a documented recent low glucose reading because the prediction incorporates treatment and clinical history.
Preventive Actions After High-Risk Identification
A predictive alert has value only when linked to a response. The first step is medication reconciliation and individualized review. Clinicians should determine whether doses remain appropriate, whether kidney function or food intake has changed, and whether a less hypoglycemia-prone therapy is suitable. Current ADA guidance recommends considering deintensification or switching away from medications that cause hypoglycemia when the risks exceed the benefits. Glycemic targets should reflect the patient’s health status and preferences rather than a universal number.
Education should address symptom recognition, glucose confirmation when possible, prompt treatment, rechecking, and prevention of recurrence. Patients using insulin or otherwise at meaningful risk should know how activity, delayed meals, illness, and alcohol may affect glucose. Family members or caregivers may need instruction, especially when the patient has impaired awareness or has experienced a level 3 event. Glucagon should be prescribed for people at increased risk of severe hypoglycemia, and those likely to assist should know where it is and how to use it.
Continuous glucose monitoring can provide trend information and alerts that help many insulin-treated patients detect falling glucose earlier. It is not a complete solution: patients need access, training, appropriate alert settings, and a plan for responding. Food insecurity, unstable housing, medication cost, language barriers, and limited ability to attend follow-up may also increase danger. Effective prevention therefore combines clinical treatment with assessment of social circumstances.
Role of Health Systems
The tool was developed partly to enable systematic outreach. An electronic health record can identify a high-risk population and generate lists for pharmacists, nurses, diabetes educators, or primary-care teams. Interventions may include medication review, telehealth contact, follow-up after discharge, referral for education, provision of monitoring supplies, or assessment for food and transportation needs. Such programs should define responsibility clearly so that an alert does not appear without anyone acting on it.
Health systems should evaluate whether implementation reduces severe events, improves patient experience, and avoids unintended consequences. Excessive alerts can produce fatigue. Poorly designed risk flags can stigmatize patients or encourage clinicians to relax glucose management without discussion. Outcomes should therefore include hypoglycemia, hyperglycemia, quality of life, treatment burden, and equity. Patients should be involved in deciding what form of prevention is acceptable.
Limitations of Predictive Models
Prediction is not causation. The model identifies associations and cannot explain why a particular patient will experience an event. Administrative records may miss episodes treated at home or outside the health system. Coding may be incomplete, and variables such as cognitive status, meal insecurity, health literacy, alcohol use, or living alone may not be represented. A tool validated in large health systems may perform differently in another country, insurance system, or demographic group.
Machine-learning and statistical tools also require monitoring for bias. If some groups have less access to emergency care, their recorded event rate may appear lower even when their true risk is substantial. A model can reproduce such patterns. Clinicians should therefore treat the score as one input and invite the patient’s account of symptoms, routines, barriers, and goals.
Conclusion
The Karter hypoglycemia risk-stratification tool was an important patient-safety innovation because it reduced a complex prediction problem to six routinely available variables and identified adults with type 2 diabetes who might benefit from focused prevention. Its purpose is not to label patients or replace clinical judgment. The score should lead to medication review, individualized glycemic goals, education, monitoring support, glucagon access when indicated, and attention to kidney function, nutrition, cognition, and social barriers. Current ADA guidance reinforces the need to assess hypoglycemia at every relevant encounter and to modify treatment after significant events. Used responsibly and revalidated over time, risk assessment can help health systems prevent avoidable emergency visits while preserving the benefits of effective diabetes care.
References
American Diabetes Association Professional Practice Committee. (2026). Glycemic goals, hypoglycemia, and hyperglycemic crises: Standards of Care in Diabetes—2026. Diabetes Care, 49(Supplement 1).
American Diabetes Association Professional Practice Committee. (2026). Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes—2026. Diabetes Care, 49(Supplement 1).
Karter, A. J., Warton, E. M., Lipska, K. J., Ralston, J. D., Moffet, H. H., Jackson, G. G., Huang, E. S., & Miller, D. R. (2017). Development and validation of a tool to identify patients with type 2 diabetes at high risk of hypoglycemia-related emergency department or hospital use. JAMA Internal Medicine, 177(10), 1461–1470. https://doi.org/10.1001/jamainternmed.2017.3844
Reusch, J. E. B., & Manson, J. E. (2017). Management of type 2 diabetes in 2017: Getting to goal. JAMA, 317(10), 1015–1016.
Cite This Work
To export a reference to this article please select a referencing stye below:
Academic Master Education Team is a group of academic editors and subject specialists responsible for producing structured, research-backed essays across multiple disciplines. Each article is developed following Academic Master’s Editorial Policy and supported by credible academic references. The team ensures clarity, citation accuracy, and adherence to ethical academic writing standards
Content reviewed under Academic Master Editorial Policy.
